核苷(酸)类药物抗病毒过程中HBV RNA变化临床意义的研究
2021-03-24姜明霞于俊洲王卫东王红梅于连英徐守芳吕思锐
姜明霞 于俊洲 王卫东 王红梅 于连英 徐守芳 吕思锐

【摘要】 目的:探討核苷(酸)类药物抗病毒过程中HBV RNA变化的临床意义。方法:选择2018年2月-2019年2月慢性乙型肝炎患者400例,所有患者均为初治患者。采用随机数字表法将患者分为对照组和观察组,每组200例。对照组恩替卡韦采用治疗,观察组采用替诺福韦治疗。比较两组HBV RNA与各生化指标。结果:治疗前及治疗96周后,两组生化指标比较,差异均无统计学意义(P>0.05);治疗96周后,两组ALT、AST、TBIL、HBsAg、HBeAg水平均低于治疗前,PTA水平高于治疗前(P<0.05)。治疗前及治疗96周后,两组肝脏纤维化水平比较,差异均无统计学意义(P>0.05);治疗96周后,两组LN、HA、PCⅢ及Ⅳ-C水平均低于治疗前,差异均有统计学意义(P<0.05)。治疗前,两组HBV RNA水平比较,差异无统计学意义(P>0.05)。治疗方法与治疗时间存在交互作用(F组间×时间=6.131,P组间×时间<0.05)。结论:核苷(酸)类药物抗病毒过程中HBV RNA变化能反映患者病情恢复情况,能指导临床治疗,可获得良好的预后,值得推广应用。
【关键词】 核苷(酸)类药物 抗病毒 HBV RNA变化
Study on Clinical Significance of HBV RNA Changes During Antiviral Treatment of Nucleoside (Acid) Drugs/JIANG Mingxia, YU Junzhou, WANG Weidong, WANG Hongmei, YU Lianying, XU Shoufang, LYU Sirui. //Medical Innovation of China, 2021, 18(16): -139
[Abstract] Objective: To explore the clinical significance of HBV RNA changes in the antiviral process of nucleoside (acid) drugs. Method: A total of 400 patients with chronic hepatitis B from February 2018 to February 2019 were selected, and all the patients were newly treated. The patients were divided into control group and observation group by random number table method, 200 cases in each group. The control group was treated with Entecavir and the observation group was treated with Tenofovir. HBV RNA and biochemical indexes were compared between the two groups. Result: Before treatment and 96 weeks after treatment, there were no significant differences in biochemical indexes between the two groups (P>0.05). After 96 weeks of treatment, the levels of ALT, AST, TBIL, HBsAg and HBeAg in both groups were lower than before treatment, and the levels of PTA were higher than before treatment (P<0.05). Before treatment and 96 weeks after treatment, there were no significant differences in liver fibrosis level between the two groups (P>0.05). After 96 weeks of treatment, the levels of LN, HA, PCⅢ and Ⅳ-C in both groups were lower than those of before treatment, the differences were statistically significant (P<0.05). Before treatment, there was no significant difference in HBV RNA level between the two groups (P>0.05). There was an interaction between treatment method and treatment time (Fgroup×time=6.131, Pgroup×time<0.05). Conclusion: The changes of HBV RNA in the antiviral process of nucleoside (acid) drugs can reflect the patient’s condition recovery, can guide clinical treatment, and can obtain a good prognosis, which is worthy of popularization and application.
[Key words] Nucleoside (acid) drugs Antiviral HBV RNA changes
First-author’s address: Jiamusi Infectious Disease Hospital, Jiamusi 154007, China
doi:10.3969/j.issn.1674-4985.2021.16.033
数据调查结果表明:全球约有20亿人曾感染HBV,且约有2.4亿人为慢性HBV感染者[1];每年约有65万人死于HBV所致的肝衰竭、肝硬化与肝癌。临床研究表明:我国慢性肝病患者多数是由于HBV感染引起,且超过80.0%的肝癌患者具有肝硬化背景,且我国HBV感染者已经达到7 800万,慢性乙肝患者约2 000万,影响我国居民健康、生活[2]。抗乙肝病毒药物核苷酸类药物(NAs)及长效干扰素是慢性乙型肝炎患者治疗中常用的抗病毒药物,虽然能延缓病情发展,但是均无法有效清除病毒、实现临床治愈[3-4]。……
